Loading data for MPLT — first visit, this takes a few seconds.

MapLight Therapeutics, Inc. (MPLT)

NasdaqGS: MPLT · 即時價格 · USD

13.77

+0.63 (4.79%)

收盤價： Sep 11, 2026, 3:59 PM

13.00

+0.00%

盤後: 7:30 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

4.79% (1D)

買價	14.06
市值	603M
營收 (ttm)	n/a
淨利（ttm）	-230M
	0.00
	-18.72
	n/a
	-3.94
P/B (ttm)	1.70
P/S (ttm)	0.00
財報日期	Nov 12, 2026

賣價	14.05
成交量	550,854
20 日平均成交量	859,053
開盤價	13.03
前收盤價	13.14
當日區間	13.00 - 14.14
52 週範圍	9.10 - 40.43
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 MPLT

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Oct 27, 2025

員工 133

證券交易所 NasdaqGS

股票代號 MPLT

網站 https://www.maplightrx.com

完整的公司簡介

財務表現

MapLight Therapeutics 在 2025 年的營收為 0，較前一年的 n/a 增加 undefined%。淨利為 -161.15M，較前期增加 undefined%。

財務報表

財報驚奇

MapLight Therapeutics 已於 Aug 13, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -1.32 低於預期 -0.01, 年增 -Infinity% 下滑.

下次財報發布

MapLight Therapeutics, Inc. 的下次財報預計於 Nov 12, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

3 週前 · BioPharma Dive

AstraZeneca scores in lung cancer; Sandoz inks a China deal

A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.

4 週前 · MT Newswires

MapLight Therapeutics Launching $150 Million Private Placement Financing

MapLight Therapeutics (MPLT) said Thursday it has signed an agreement with investors to sell securit

1 月前 · BioPharma Dive

MapLight CEO on what investors missed in the biotech’s schizophrenia data

Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."

1 月前 · Clinical Trials Arena

MapLight Therapeutics stock crashes on Phase II schizophrenia data

MapLight said the twice-daily dose met the primary endpoint of the schizophrenia trial, but the daily dose did not.

1 月前 · Stocktwits

MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose

MapLight announced topline findings from its mid-stage ZEPHYR trial of ML-007C-MA, an oral medicine tested in about 307 adults hospitalized for a sudden worsening of schizophrenia symptoms, on Monday.

第 1 頁，共 2 頁

MapLight Therapeutics, Inc. (MPLT)